At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Durvalumab, AZD2811, and 3 other interventions for Small-Cell Lung Cancer. Active but no longer recruiting, targeting 31 participants across 12 sites in 4 countries.
Detailed Summary
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.
Study Details
Timeline
Interventions
IV infusions through induction phase. IV infusions through maintenance phase until PD or other discontinuation criteria.
IV infusions through maintenance phase until PD or other discontinuation criteria.
IV infusions through induction phase if chosen by Investigator.
IV infusions through induction phase if chosen by Investigator.
IV infusions through induction phase.